Description

Human G-Csf CAS NO 62683-29-8 is a recombinant human granulocyte colony-stimulating factor, a vital hematopoietic growth factor that stimulates the production, differentiation, and function of neutrophil granulocytes. This protein is of paramount importance in modern medicine for its ability to accelerate neutrophil recovery following myelosuppressive chemotherapy or bone marrow transplantation. It is an essential raw material for the pharmaceutical industry, primarily used in the development and manufacturing of biotherapeutic drugs targeting neutropenia. Key sectors requiring this high-purity biological include biopharmaceutical manufacturers, clinical research organizations, and diagnostic kit developers.

Application

• Pharmaceutical Active Ingredient: Primary use as the active pharmaceutical ingredient (API) in injectable formulations for the treatment of chemotherapy-induced neutropenia.
• Oncology Supportive Care: Critical component in drugs used to reduce the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs.
• Bone Marrow Transplantation: Used in therapeutic agents to mobilize hematopoietic progenitor cells into the peripheral blood for collection and subsequent autologous transplantation.
• Severe Chronic Neutropenia (SCN): Employed in the manufacture of treatments for congenital, cyclic, or idiopathic neutropenia to increase neutrophil counts and reduce infections.
• Research & Development: Serves as a critical standard and reagent in biomedical research for studying hematopoiesis, immune cell function, and cytokine signaling pathways.
• Diagnostic Manufacturing: Used as a calibrated reference standard in the production of ELISA kits and other immunoassays for quantifying G-CSF levels in clinical samples.
• Biosimilar Development: Essential reference material for companies developing biosimilar versions of branded G-CSF therapeutics, requiring high-purity, well-characterized material.

Basic Information

Product Name	Human G-Csf
CAS No.	62683-29-8
Molecular Formula	C845H1343N223O243S9
Molecular Weight	Approx. 18,800 Da
Synonyms	Granulocyte Colony-Stimulating Factor; G-CSF; Filgrastim; Lenograstim; Plerixafor; Colony Stimulating Factor 3 (CSF3); Granulocyte Colony Stimulating Factor (Human); Recombinant Human G-CSF; rhG-CSF; CSF-3; MGI-1G; MGC45931
EINECS	Contact for details

Quality Control

Our Human G-Csf is manufactured under strict quality management systems. Each batch is subjected to a comprehensive battery of analytical tests to ensure identity, purity, potency, and safety, aligning with ICH Q6B guidelines for biotechnological products. We provide full traceability and Certificates of Analysis (COA) detailing specifications for purity (by HPLC), biological activity (cell-based proliferation assay), endotoxin levels, and identity confirmation (mass spectrometry, peptide mapping). The material is suitable for use in GMP-compliant pharmaceutical manufacturing processes.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store lyophilized powder at -20°C or below. Reconstituted solutions should be used immediately or stored at 2-8°C for short periods as per validated stability data. The product is hygroscopic (moisture-sensitive); ensure containers are sealed under controlled humidity conditions to prevent degradation.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder
Identification (Mass Spec)	Conforms
Purity (RP-HPLC)	≥ 98.0%
Biological Activity	≥ 1.0 x 108 IU/mg
Endotoxin	< 10 EU/mg
Protein Content (UV)	≥ 95.0%
Moisture (Karl Fischer)	≤ 3.0%
Sterility (Membrane Filtration)	Sterile

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.